Vnitr Lek 2021, 67(5):258-263 | DOI: 10.36290/vnl.2021.072

Bone disesase in end-stage kidney disease - renal and non-renal components

Sylvie Dusilová Sulková1, Anita Pokorná1, Roman Šafránek1, Ladislava Pavlíková2, Vladimír Palička2
1 Hemodialyzační středisko FN Hradec Králové a katedra interních oborů, Lékařská fakulta UK v Hradci Králové
2 Ústav klinické biochemie a diagnostiky, FN Hradec Králové

Metabolic bone disease in chronic kidney disease and end-stage renal failure represents one of the most severe clinical complication in kidney patients, namely those on maintenance dialysis. Traditionally, bone changes are induced by secondary hyperparathyroidism. The CKD-MBD concept reflects the link between bone and cardiovascular disease in these patients. Studies documented also other bone pathological pathways in renal patients, such as osteoporosis, as in kidney and dialysis patients its risk factors are present as well as in general population. Resulting bone disease in renal disease and failure is far more complex than previously seen. However, the secondary hyperparathyroidism still represents the main pathological pathway.

Keywords: chronic kidney disease, renal bone disease, dialysis, secondary hyperparathyroidism, hyperphosphatemia, FGF-23, parathyroid hormone, osteoporosis in kidney disease.

Published: August 25, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dusilová Sulková S, Pokorná A, Šafránek R, Pavlíková L, Palička V. Bone disesase in end-stage kidney disease - renal and non-renal components. Vnitr Lek. 2021;67(5):258-263. doi: 10.36290/vnl.2021.072.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Moe S, Drüeke T, Cunningham J et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69(11): 1945-1953. Go to original source... Go to PubMed...
    2. Ketteler M, Block GA, Evenepoel P et al. Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med. 2018; 168(6): 422-430. Go to original source... Go to PubMed...
    3. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011; 6: 913-921. Go to original source... Go to PubMed...
    4. Cannata-Andía JB, Martín-Carro B, Martín-Vírgala J et al. Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management. Calcif Tissue Int 2021; 108: 410-422. Go to original source... Go to PubMed...
    5. Jørgensen HS, David K, Salam S. et al. European Renal Osteodystrophy (EUROD) workgroup, an initiative of the CKD-MBD working group of the ERA-EDTA. Traditional and Non-traditional Risk Factors for Osteoporosis in CKD. Calcif Tissue Int. 2021; 108: 496-511. Go to original source... Go to PubMed...
    6. Evenepoel P, Cunningham J, Ferrari S et al. European Renal Osteodystrophy (EUROD) workgroup, an initiative of the CKD-MBD working group of the ERA-EDTA, and the committee of Scientific Advisors and National Societies of the IOF. European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transplant. 2021; 36: 42-59. Go to original source... Go to PubMed...
    7. Vilaca T, Salam S, Schini M et al. Risks of Hip and Nonvertebral Fractures in Patients with CKD G3a-G5D: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2020; 76: 521-532. Go to original source... Go to PubMed...
    8. Hampson G, Elder GJ, Cohen-Solal M et al. Abrahamsen B. A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. Endocrine. 2021 May 11. doi: 10.1007/s12020-021-02735-9. Go to original source... Go to PubMed...
    9. Brunerova L, Palicka V, Dusilova Sulkova S. Commentary on Management of Osteoporosis in Advanced CKD: Common View of a Nephrologist and a Bone Specialist. Endocrine Practice 2019; 25: 193-196. Go to original source... Go to PubMed...
    10. Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol 2015; 10: 1257-1272. Go to original source... Go to PubMed...
    11. Tatsumi S, Miyagawa A, Kaneko I et al. Regulation of renal phosphate handling: inter-organ communication in health and disease. J Bone Miner Metab. 2016; 34: 1-10. Go to original source... Go to PubMed...
    12. Ureña-Torres PA, Vervloet M, Mazzaferro S et al. ERA-EDTA CKD-MBD Working Group. Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. Clin Kidney J 2018; 12: 269-280. Go to original source... Go to PubMed...
    13. Bover J, Arana C, Ureña P et al. Hyporesponsiveness or resistance to the action of parathyroid hormone in chronic kidney disease. Nefrologia (Engl Ed). 2021; doi: 10.1016/j.nefro.2020.12.019. Go to original source... Go to PubMed...
    14. Goto S, Fuji H, Hamada Y et al. Association between indoxyl sulphate and skeletal resistance in hemodialysis patients. Ther Apher Dial. 2010; 14: 417-423. Go to original source... Go to PubMed...
    15. Watanabe K, Tominari T, Hirata M et al. Indoxyl sulphate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption. FEBS Open Bio. 2017; 20(7): 1178-1185. Go to original source... Go to PubMed...
    16. Yamamoto S, Fukagawa M. Uremic Toxicity and Bone in CKD. J Nephrol. 2017; 30: 623-627. Go to original source... Go to PubMed...
    17. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124-136. Go to original source... Go to PubMed...
    18. Graciolli FG, Neves KR, dos Reis LM et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol Dial Transplant. 2009; 24: 1416-1421. Go to original source... Go to PubMed...
    19. Schlieper G, Schurgers L, Brandenburg V et al. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant 2015. Go to original source... Go to PubMed...
    20. Graciolli FG, Neves KR, dos Reis LM et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol Dial Transplant. 2009; 24: 1416-1421. Go to original source... Go to PubMed...
    21. Carrilo-Lopez N, Panizo S, Alonso-Montes C et al. High serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcifications in experimental chronic kidney disease. Nephrol Dial Transplant 2018; 34: 934-941. Go to original source... Go to PubMed...
    22. Razzaque MS. The dualistic role of vitamin D in vascular calcifications Kidney Int. 2011; 79: 708-714. Go to original source... Go to PubMed...
    23. Dusilová Sulková S, Horáček J, Vykoukalová E et al. Parathyroidectomy in Hyperparathyroidism-Associated Calciphylaxis in End-Stage Renal Disease Should be Prompt and Radical - a Case Report with Two Original Therapeutic Modifications and Successful Outcome. Acta Medica (Hradec Kralove). 2017; 60: 85-88. Go to original source... Go to PubMed...
    24. Duque EJ, Elias RM, Moysés RMA. Parathyroid Hormone: A Uremic Toxin. Toxins (Basel). 2020; 12:189. doi: 10.3390/toxins12030189. Go to original source... Go to PubMed...
    25. Silver J, Naveh-Many T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol 2013; 9: 641-649. Go to original source... Go to PubMed...
    26. Ketteler M, Ambühl P. Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease. J Nephrol. 2021; doi: 10.1007/s40620-021-01082-2. Go to original source... Go to PubMed...
    27. Komaba H, Ketteler M, Cunningham J et al. Old and New Drugs for the Management of Bone Disorders in CKD. Calcif Tissue Int. 2021; 108: 486-495. Go to original source... Go to PubMed...
    28. Shutto Y, Shimada M, Kitajima M et al. Lack of awareness among future medical professionals about the risk of consuming hidden phosphate- containing processed food and drinks. PLoS One. 2011; 6: e29105. Go to original source... Go to PubMed...
    29. D'Alessandro C, Piccoli GB, Cupisti A. The "phosphorus pyramid": a visual tool for dietary phosphate management in dialysis and CKD patients. BMC Nephrol. 2015; 16: 9. Go to original source... Go to PubMed...
    30. Christodoulou M, Aspray TJ, Schoenmakers I. Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of Guidelines. Calcif Tissue Int. 2021 Apr 25. doi: 10.1007/s00223-021-00844-1. Go to original source... Go to PubMed...
    31. Sista SK, Arum SM. Management of adynamic bone disease in chronic kidney disease: A brief review. J Clin Transl Endocrinol 2016; 5: 32-35. Go to original source... Go to PubMed...
    32. Dusilová-Sulková S, Šafránek R, Vávrová J et al. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients. Int Urol Nephrol 2015; 47: 169-176. Go to original source... Go to PubMed...
    33. Hu MC, Kuro-o M, Moe OW. The emerging role of Klotho in clinical nephrology. Nephrol Dial Transplant 2012; 27(7): 2650-2657. Go to original source... Go to PubMed...
    34. Drueke TB, Massy ZA. Changing bone patterns with progression of chronic kidney disease. Kidney Int 2016; 89(2): 289-302. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.